Gentle for the newborn, efficient for you.
error and time consumption. Until now. D-7346-2009 While neonatal jaundice – or hyperbilirubinemia – occurs in almost all babies, it is a cause of concern for care-givers and anxiety for families. If not treated in time, neonatal jaundice can lead to permanent brain damage1 Screening for jaundice by visual assessment can lead to an overestimation of risk, which means unnecessarylab tests. This blood draw (total serum bilirubin testing (TsB)) requires a heel prick, which is painful for the baby and costly for the hospital. Visual assessment can also lead to an underestimation of risk, which could result in a failure to obtain necessary lab tests. That’s why transcutaneous bilirubin testing (TcB) has grown rapidly in the past few years as a standard practice in hospitals to identify at-risk infants. But even TcB has presented challenges in terms of human.
NEXT-GENERATION JAUNDICE SCREENING FROM DRÄGER
Building on more than 30 years of proven technology 2 he Dräger Jaundice Meter JM-105 is a non-invasive transcutaneous bilirubinometer that measures the yellow- ess of subcutaneous tissue in newborn infants as young as 24 weeks gestational age3 a transfusion or phototherapy. It provides a visual digital measurement that correlates with serum bilirubin results. Effective on heterogeneous populations, the JM-105 can be used in both hospitals and outpatient settings. The JM-105 improves the process of jaundice screening in several ways. The risk of infection is reduced since screening with the JM-105 is non-invasive and drawing blood is not necessary. The device also reduces risk of human
error because it can scan nurse and baby ID information with an optional bar code scanner and can automatically measure, save and transfer data. Not only does this eliminate manual transcription – which can be error prone and time consuming – but it also results in quicker access to information for decision making. , ho have not undergone Readmission Rate for Hyperbilirubinemia. Clinical Chemistry 2005;51 D-94479-2013 Screening with the JM-105 is cost effective because it reduces the frequency of lab tests. And because the device has a reusable probe, expensive disposables are not needed.
Because bilirubin levels peak two to four days after birth – when most babies have gone home – jaundiced babies have to be readmitted for treatment. Since the JM-105 can detect this risk before babies leave the hospital, jaundice can be treated immediately, which can reduce readmissions and lengths of stay 4 .